SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response

Ann Rheum Dis. 2021 Oct;80(10):1355-1356. doi: 10.1136/annrheumdis-2021-220408. Epub 2021 May 6.

Authors

Michael Markus Bonelli¹, Daniel Mrak¹, Thomas Perkmann², Helmuth Haslacher², Daniel Aletaha³

Affiliations

¹ Division of Rheumatology, Medical University of Vienna, Vienna, Austria.
² Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
³ Division of Rheumatology, Medical University of Vienna, Vienna, Austria daniel.aletaha@meduniwien.ac.at.

PMID: 33958323
DOI: 10.1136/annrheumdis-2021-220408

No abstract available

Keywords: B-lymphocytes; COVID-19; rituximab.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Viral / blood
Antibodies, Viral / immunology
Antirheumatic Agents / therapeutic use
BNT162 Vaccine
COVID-19 / prevention & control*
COVID-19 Vaccines / immunology*
Humans
Immunity, Cellular / drug effects
Immunity, Cellular / immunology
Immunity, Humoral / drug effects
Immunity, Humoral / immunology
Immunocompromised Host / immunology*
Immunogenicity, Vaccine / drug effects*
Immunogenicity, Vaccine / immunology
Rheumatic Diseases / drug therapy
Rheumatic Diseases / immunology*
Rituximab / therapeutic use*
SARS-CoV-2

Substances

Antibodies, Viral
Antirheumatic Agents
COVID-19 Vaccines
Rituximab
BNT162 Vaccine